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Review of the Effectiveness of Tissue Plasminogen Activator for the Treatment of Plastic Bronchitis
in Patients with Fontan Physiology
Ruth Ferroni, BSN, RN, CCRN
Otterbein University, Westerville, Ohio
Introduction
Plastic bronchitis is a condition characterized by the formation of bronchial casts ranging
from small to large obstructions of the pulmonary airways. Cast formation is intricate and
resembles a plastic, rubbery model of the airway it obstructs. Its form was first described by
Galen (A.D. 131-200). One of the patient populations at risk for developing this rare
complication are those with single ventricle disease who are surgically corrected to Fontan
physiology. It is a very abnormal type of circulation that is suspect in the development of
plastic bronchitis. The cellular composition of plastic bronchitis differs from the casts seen in
patients with chronic respiratory diseases such as asthma or lymphatic disorders of the lung
and, as a result, complete airway obstruction may occur more quickly with a resultant lifethreatening and possibly fatal event.
Bronchial casts may also be seen in other disease states such as sickle cell disease,
metastatic lung tumors, bronchopulmonary aspergillosis, thalassemia alpha, and inhalation
injuries (Do, Randhawa, Chin, Parsapour, & Nussbaum, 2012). Tissue plasminogen activator
in an aerosolized form has shown to be effective therapy in most cases. The following
information is an update on the adaptation of this therapy in the last 5 years.

Signs and Symptoms
The most common presenting symptoms are cough
and intermittent dyspnea (Goldberg, Rychik, &
Dodds, 2010). The cough may be productive or nonproductive depending on the patient’s ability to
expectorate casts. Frequently, thick mucus is
expectorated with a mucus plug consistency which
can be deceiving as the mucus plugs may actually be
fragments breaking away from the cast. Chest pain
and fever are also reported but occurs more
frequently in patients with pulmonary parenchymal
disease. Cardiac patients rarely exhibit
a fever, and blood and sputum cultures are usually
negative (Heath et al., 2011). Breath sounds may be
diminished, coarse, and wheezing may be present.
Chest x-ray reveals opacity and consolidated lung
fields similar to pneumonia and, bronchoscopy or
expectoration of a cast is the only reliable
determinant of the diagnosis. See figure 2.

Pathophysiology
Fontan physiology (or circulation) involves hooking up systemic venous return directly to the
branch pulmonary artery(s) thus bypassing the right side of the heart. This is also referred to
as “passive circulation” and forward blood flow through the lungs is accomplished by pressure
gradients between the central venous circulation and the pulmonary vascular bed. The
etiology is unclear, however increased pulmonary venous pressures may contribute to
affecting the respiratory epithelium and interruption of the bronchial mucosa causing
proteinaceous material to leak and hypersecretion of mucus with resultant cast formation.
Histology samples of patients with congenital heart disease reveal acellular casts with mucin
and fibrin and the absence of Charcot –Leyden crystals . Patients with primary pulmonary
diseases reveal a combination of inflammatory casts, eosinophils, Charcot –Leyden crystals
and mucin thought t o be due to chronic bronchial inflammation (Do, 2009; Goldberg, 2010;
Singhal, 2013). See figure 1.

Figure 2.

Treatment
Once the airway is stabilized, patients with congenital heart disease suffering from the rare
complication of plastic bronchitis are first evaluated for circulatory efficiency. A cardiac catheterization
is performed to determine venous systemic and pulmonary pressures, development of collateral
circulation in the lungs, narrow pulmonary vessels and evaluation of the Fontan circuit. The Fontan
conduit may be fenestrated to reduce systemic venous pressure; narrowed blood vessels may be
stented open, collaterals closed with obstructive devices and the functioning cardiac valve and ventricle
assessed for optimum performance. Fontan physiology, at its best outcome mimics chronic, low grade
congestive heart failure. Every effort is made to decrease systemic venous pressures and optimize
cardiac output (Goldberg, et al.,2010). However, there is no guarantee of successful prevention of a
recurrence of plastic bronchitis. If histology shows dilated lymphatics, thoracic duct ligation is also
considered especially if the patient exhibits problems with pleural effusions. (Colanari, Quarti, Pozzi,
Gasparini, Carloni, & de Benedictis, 2014)
Pharmacological therapy interventions include systemic and inhaled corticosteroids, mucolytics such as
acetylcysteine and dornase alpha, and fibrinolytics namely Urokinase and Alteplase.
Tissue plasminogen activator (tPA) or Alteplase, is a serine protease that leads to localized fibrinolysis
by converting plasminogen to plasmin. According to the literature topical application and nebulized tPA
has been the most successful treatment without adverse effects in several case reports of children with
congenital heart disease complicated by cast bronchitis. Brogan et al. (as cited by Do et al., 2012)
isolated and incubated a bronchial cast from a Fontan patient and topically applied saline, Urokinase
and Alteplase. The saline produced no effect, the Urokinase made the cast softer and, the sample
treated with Alteplase, completely dissolved. See figure 3.
Figure 3.

The left picture shows cast fragments wedged in the upper and lower lobes.
The picture on the right shows the effect of tPA application after 15
minutes. Copyright 2012 American Academy of Pediatrics

Figure 1
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(a) Expectorated cast. (b) Cast extracted during
flexible bronchoscopy.
Copyright 2013 Hindawi Publishing Corporation.
Slide (a) reveals hypocellular fibrinous casts. Slide (b) reveals inflammatory
casts with eosinophils, Charcot-Leyden crystals and mucin.
Copyright 2013 Hindawi Publishing Corporation.

The acute phase of illness requires care to be focused on protecting and maintaining a patent
airway and preventing acute deterioration due to sudden obstruction. Extreme occlusion may
require high frequency ventilation with intermittent bronchoscopies performed to treat casts
topically and safely remove them. Once the airways are cleared, emphasis is placed on long term
supportive care, and determining a medication regime that effectively prevents recurrence if
possible.
Patient and caregiver teaching are vitally important for patient safety and quality of life. Common
upper respiratory illnesses or worsening congestive heart failure symptoms may confound the signs
and symptoms of plastic bronchitis especially if the cough is non-productive.
Education regarding chest physiotherapy techniques, maintaining a consistent medication schedule
and prompt notification of their physician and healthcare team cannot be over- emphasized since
there has been no established pattern to the recurrence of cast formation. Its onset may be sudden
or develop over time. Coordination with emergency medical services in the patient’s community
promotes prompt transfer to a tertiary center familiar with the disease process and capable of
treating acute airway issues. Family caregivers must comprehend the need to intervene quickly
when a cough and dyspnea develops by notifying their cardiologist as soon as the symptoms appear
and information taught needs to be return demonstrated by the “teach back” method to the nurse.
Close monitoring of a recurrence is essential. Journals are helpful to parents and caregivers for
tracking signs, symptoms, medication dosing and frequency, and the patient’s general state of
health. Important contact numbers should be listed in the front of the journal for easy access.

Conclusion
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Kunder et al. (2013) report one of the largest case
studies of plastic bronchitis retrospectively reviewed
which included eight patients with Fontan physiology
in the cohort and state that:
“the mechanism of cast formation remains unclear
both for the inflammatory casts
associated with lung disease and the hypocellular
casts associated with congenital heart
disease. Currently, data are limited regarding
optimal treatment of plastic bronchitis, so
the clinician must rely on individual anecdotal case
reports to guide therapy. “ The occurrence rate is
estimated to be from 4 to 14% with a poor
prognosis .
Alteplase has been proven to effectively dissolve
bronchial casts yet optimal dosing strategy and
length of maintenance therapy remain unknown.
Some patients have responded with just one dose
during the acute phase while others require home
nebulization every 6 hours for months after the
initial hospitalization. There have been no observed
side effects with tPA yet the volume of patients
reported in the literature is statistically too low to
prove best outcomes or how to achieve best
outcomes with a specific dosing regimen. There is
also a major concern regarding the expense of tPA
therapy and the reluctance of third party payers to
cover the cost so determining the amount required
for minimal efficient dosing facilitates better
insurance coverage of the treatment options for
these patients.
An international plastic bronchitis registry to collect
data on patients has been established to hopefully
resolve questions about the pathophysiology of the
disease and the most effective treatment.
(www.clinicaltrials.gov, NCT0166398)
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